← All posts
Guide20 Nov 20268 min read

503A vs 503B compounding: which rules apply

The difference between a 503A compounding pharmacy and a 503B outsourcing facility, side by side, plus what recent FDA warning letters show about CGMP at 503B sites and claims by telehealth sellers.

FDA Brief team

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act set out two different ways to compound drugs legally in the U.S. Neither path requires FDA approval of the finished drug. But they come with very different rules, regulators and risks.

In one line: 503A is a pharmacy compounding for individual patients, regulated mainly by its state board. 503B is an outsourcing facility making larger batches, registered with FDA and held to the same manufacturing rules as drug makers.

Side by side

503A compounding pharmacy503B outsourcing facility
WhoA licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physicianA facility at one address that registers with FDA as an outsourcing facility
PrescriptionsNeeded for an identified patient (limited amounts can be made ahead based on history)Not needed. Can supply hospitals and clinics as office stock
Main regulatorState board of pharmacyFDA
Manufacturing standardNot required to meet CGMP. USP chapters and state rules applyMust meet CGMP (21 CFR parts 210 and 211)
FDA inspectionsMainly when FDA has a reason, such as a complaintOn a risk-based schedule
Sterile drugsAllowedThe defining activity. Non-sterile is also allowed
Bulk drug substancesUSP or NF monograph, part of an approved drug, or on the 503A bulks listOn the 503B bulks list, or the drug is on FDA's shortage list
Reporting to FDANone routineProduct reports twice a year and adverse event reports
LabelsPatient-specificMust say "This is a compounded drug" and carry required details
FeesNone to FDAAnnual establishment fee
Copies of approved drugsNot regularly or in inordinate amountsNot allowed, unless the drug is on the shortage list

The CGMP difference is the big one

Because 503B facilities must follow CGMP, their warning letters read like letters to any drug manufacturer. Two recent examples:

  • SCA Pharmaceuticals, Little Rock, Arkansas, registered as an outsourcing facility since December 2013. FDA cited poor aseptic practice, microbial contamination in an ISO 5 area, foreign material in syringe stoppers and missing investigations under 21 CFR 211.192.
  • Pine Pharmaceuticals, Tonawanda, New York. Operators moved materials and hands from the ISO 7 cleanroom into the ISO 5 hood without sanitizing them, environmental monitoring missed high-touch staging trays, and a particulate complaint never got a root cause.

Both letters cite the same CGMP sections a large drug plant would see: 211.113(b) for contamination control, 211.192 for investigations, and 211.25 or 211.42 for training and facilities. If you are moving from 503A to 503B, this is the shift: your quality system has to stand up to a drug-plant inspection.

Telehealth sellers and "FDA-approved pharmacy"

A third group sits outside both sections: companies that sell compounded drugs without making them. In June 2026 FDA sent a batch of letters to telehealth sites selling compounded semaglutide and tirzepatide, including HydraMed and Medica Weight Loss.

The problems were claims, not manufacturing:

  • Product images carried the seller's own name, as if it made the drug.
  • The sites said products came from an "FDA-approved pharmacy." FDA does not approve or license pharmacies or outsourcing facilities.
  • Some said the compounded products themselves were FDA-approved. Compounded drugs are not.

FDA treated these claims as misbranding. If you sell or market compounded drugs, the safe wording is plain: the drug is compounded, it is not FDA-approved, and the pharmacy or outsourcing facility that makes it is named accurately.

Animal drugs follow their own rules. FDA's letter to Epicur Pharma covered website claims comparing compounded animal drugs to approved ones and statements about 503B status that FDA called misleading.

How many compounding letters FDA sends

Warning letters with compounding in the subject, by year of issue, from FDA Brief's database:

YearLetters
202114
20228
20239
20245
202514
2026 (to mid November)10

That count leaves out letters filed under other subjects, such as CGMP letters to outsourcing facilities like SCA and the telehealth claims letters, so the real number of compounding-related letters is higher.

Which one are you?

  • You fill prescriptions for individual patients: 503A, with your state board as the main regulator.
  • You want to sell to hospitals and clinics without patient prescriptions: you need to register as a 503B outsourcing facility and run to CGMP.
  • You market or sell compounded drugs made by someone else: neither section covers you, but FDA's misbranding rules do, and so do your claims.

Following compounding enforcement

FDA Brief emails you new warning letters and recalls that match what you watch. A word watch on "outsourcing facility" or "semaglutide" catches the relevant letters even when the word only appears deep in the text, and you can watch your 503B supplier by name. Each letter comes with a plain-English summary of the violations and what FDA asked for. The free plan covers three watches.